首页> 外文期刊>Pharmacological reviews >Mechanisms of penile erection and basis for pharmacological treatment of erectile dysfunction.
【24h】

Mechanisms of penile erection and basis for pharmacological treatment of erectile dysfunction.

机译:阴茎勃起的机制和勃起功能障碍的药物治疗基础。

获取原文
获取原文并翻译 | 示例
       

摘要

Erection is basically a spinal reflex that can be initiated by recruitment of penile afferents, both autonomic and somatic, and supraspinal influences from visual, olfactory, and imaginary stimuli. Several central transmitters are involved in the erectile control. Dopamine, acetylcholine, nitric oxide (NO), and peptides, such as oxytocin and adrenocorticotropin/alpha-melanocyte-stimulating hormone, have a facilitatory role, whereas serotonin may be either facilitatory or inhibitory, and enkephalins are inhibitory. The balance between contractant and relaxant factors controls the degree of contraction of the smooth muscle of the corpora cavernosa (CC) and determines the functional state of the penis. Noradrenaline contracts both CC and penile vessels via stimulation of alpha-adrenoceptors. Neurogenic NO is considered the most important factor for relaxation of penile vessels and CC. The role of other mediators, released from nerves or endothelium, has not been definitely established. Erectile dysfunction (ED), defined as the "inability to achieve or maintain an erection adequate for sexual satisfaction," may have multiple causes and can be classified as psychogenic, vasculogenic or organic, neurologic, and endocrinologic. Many patients with ED respond well to the pharmacological treatments that are currently available, but there are still groups of patients in whom the response is unsatisfactory. The drugs used are able to substitute, partially or completely, the malfunctioning endogenous mechanisms that control penile erection. Most drugs have a direct action on penile tissue facilitating penile smooth muscle relaxation, including oral phosphodiesterase inhibitors and intracavernosal injections of prostaglandin E. Irrespective of the underlying cause, these drugs are effective in the majority of cases. Drugs with a central site of action have so far not been very successful. There is a need for therapeutic alternatives. This requires identification of new therapeutic targets and design of new approaches. Research in the field is expanding, and several promising new targets for future drugs have been identified.
机译:勃起基本上是一种脊柱反射,可通过招募来自视觉,嗅觉和想象刺激的阴茎传入神经(包括自主神经和躯体神经)以及脊柱上神经而引发。勃起控制中涉及几个中央变送器。多巴胺,乙酰胆碱,一氧化氮(NO)和诸如催产素和促肾上腺皮质激素/α-黑素细胞刺激激素之类的肽具有促进作用,而5-羟色胺可能具有促进作用或具有抑制作用,而脑啡肽则具有抑制作用。收缩因子和松弛因子之间的平衡控制海绵体(CC)平滑肌的收缩程度,并确定阴茎的功能状态。去甲肾上腺素通过刺激α-肾上腺素受体收缩CC和阴茎血管。神经源性NO被认为是放松阴茎血管和CC的最重要因素。从神经或内皮释放的其他介质的作用尚未明确。勃起功能障碍(ED)定义为“无法实现或维持足以满足性满足的勃起”,可能有多种原因,可分为心因性,脉管性或器质性,神经性和内分泌性。许多ED患者对目前可用的药理疗法反应良好,但仍有一些患者的反应不理想。所使用的药物能够部分或完全替代控制阴茎勃起的内源性机能障碍。大多数药物对促进阴茎平滑肌松弛的阴茎组织具有直接作用,包括口服磷酸二酯酶抑制剂和腔内注射前列腺素E。无论其潜在病因如何,这些药物在大多数情况下均有效。迄今为止,具有中心作用部位的药物还不是很成功。需要治疗选择。这就需要确定新的治疗目标和设计新的方法。该领域的研究正在扩展,并且已经确定了一些有希望的未来药物新靶标。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号